布林佐胺治疗青光眼的降眼压效果及安全性分析

目的 探讨布林佐胺治疗青光眼的降眼压效果及安全性分析.方法 选取2012年2月～2014年2月我院收治的48例90只眼原发性开角型青光眼、高眼压症及术后残余青光眼患者,随机分为观察组和对照组各24例45只眼.①观察组：采用1％布林佐胺滴眼液（派立明）治疗,分别于每日早晚8：00各给药1次,1滴/次,滴入患眼下方结膜囊内,压迫泪囊区3 min以上.②对照组：采用0.5％马来酸噻吗洛尔滴眼液（噻吗心安）治疗,分别于每日早晚8：00各给药1次,1滴/次,滴入患眼下方结膜囊内,压迫泪囊区3 min以上.分别于治疗前与治疗后第2、4、6、12周测量眼压.每次测量3次,取均值.记录患者的血压、脉率及视野的变化,监测不良反应.结果 两组患者治疗后第2、4、8、12周的眼压水平较治疗前均下降,观察组下降幅度大于对照组（P＜0.05）;观察组治疗不良反应发生率16.6％低于对照组29.2％（P＜0.05）.两组均无发生严重不良反应病例.结论 布林佐胺能有效降低患者眼压,且副作用小,患者耐受性好,是治疗青光眼的临床安全有效药物之一.

Brinzolamide treatment of glaucoma and ocular hypotensive effects of security analysis

Objective To discuss the effect and security of brinzolamide in treatment of glaucoma and ocular hypotensive. Methods Selected 48 patients 90 eyes with primary open-angle glaucoma in our hospital from February 2012 to February 2014, ocular hypertension and glaucoma surgery remnants were randomly divided into observation group and control group, 24 cases of 45 eyes. （1）observation group： 1% brinzolamide eye drops（brinzolamide） treatment, respectively, at 8：00 each morning and evening daily administration of 1, 1 drop/s, now suffering from side trickle conjunctiva oppression 3min lacrimal sac area above. （2）the control group： 0.5% timolol maleate eye drops （timolol） treatment, respectively, in the morning and evening 8：00 each administered once, 1 drop/, trickle now suffering from side conjunctiva, lacrimal sac area oppression 3min above. Before treatment and after treatment 2,4,6,12 week measuring intraocular pressure. Each measured 3 times, and the mean value. Records changes in blood pressure, pulse rate, and the patient＇s vision, monitoring of adverse reactions. Results After treatment IOP levels 2,4,8,12 week called before treatment decreased in the observation group declined more than in the control group,the difference was significant （P〈0.05）; observed incidence of adverse reactions treatment group than the control group 16.6% 29.2 %,,the difference was significant（P〈0.05）. There were no cases of serious adverse reactions. Conclusion Brinzolamide can effectively reduce intraocular pressure in patients, and side effects, patients tolerated, is one of the safe and effective clinical treatment of glaucoma drugs.